0001104659-22-004147.txt : 20220113
0001104659-22-004147.hdr.sgml : 20220113
20220113210026
ACCESSION NUMBER: 0001104659-22-004147
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220112
FILED AS OF DATE: 20220113
DATE AS OF CHANGE: 20220113
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Rawcliffe Adrian
CENTRAL INDEX KEY: 0001555851
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37368
FILM NUMBER: 22530272
MAIL ADDRESS:
STREET 1: 440 SOUTH BROAD STREET, UNIT 1906
CITY: PHILADELPHIA
STATE: PA
ZIP: 19146
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Adaptimmune Therapeutics PLC
CENTRAL INDEX KEY: 0001621227
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: X0
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 60 JUBILEE AVENUE
STREET 2: MILTON PARK
CITY: ABINGDON, OXFORDSHIRE
STATE: X0
ZIP: OX14 4RX
BUSINESS PHONE: 44 1235 430000
MAIL ADDRESS:
STREET 1: 60 JUBILEE AVENUE
STREET 2: MILTON PARK
CITY: ABINGDON, OXFORDSHIRE
STATE: X0
ZIP: OX14 4RX
FORMER COMPANY:
FORMER CONFORMED NAME: Adaptimmune Ltd
DATE OF NAME CHANGE: 20141001
4
1
tm221700-5_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2022-01-12
0
0001621227
Adaptimmune Therapeutics PLC
ADAP
0001555851
Rawcliffe Adrian
C/O ADAPTIMMUNE THERAPEUTICS PLC,
60 JUBILEE AVENUE, MILTON PARK
ABINGDON
X0
OX14 4RX
UNITED KINGDOM
1
1
0
0
Chief Executive Officer
Option to purchase Ordinary Shares
0.60
2022-01-12
4
A
0
4690224
0
A
2032-01-12
Ordinary Shares
4690224
4690224
D
Option to purchase Ordinary Shares
0.0014
2022-01-12
4
A
0
1047480
0
A
Ordinary Shares
1047480
1047480
D
The exercise price was converted from GBP0.44 based on an exchange rate of $U.S. 1.362272 to GBP1.00. The actual exercise price will be the pounds sterling amount.
Exercisable as to 1,172,556 Ordinary Shares on January 12, 2023 and will be exercisable as to the remainder in monthly installments of 97,710 Ordinary Shares on the twelfth of each month from February 12, 2023 through December 12, 2025 and 97,818 Ordinary Shares on January 12, 2026.
The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.362272 to GBP1.00. The actual exercise price will be the pounds sterling amount.
Exercisable as to 261,870 Ordinary Shares on January 12, 2023 and will be exercisable as to the remainder in annual installments of 261,870 Ordinary Shares on the twelfth of each January from January 12, 2024 through January 12, 2026.
The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.
/s/ Adrian George Rawcliffe
2022-01-13